BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 2785598)

  • 1. Pulmonary function in patients presenting with Raynaud's phenomenon without an underlying connective tissue disease. A prospective, longitudinal study.
    Aalbers R; Groen H; Postma DS; Van der Mark TW; Wouda AA; Reig RP; Kallenberg CG
    J Rheumatol; 1989 Jan; 16(1):36-41. PubMed ID: 2785598
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Early detection of connective tissue disease in patients with Raynaud's phenomenon.
    Kallenberg CG
    Rheum Dis Clin North Am; 1990 Feb; 16(1):11-30. PubMed ID: 2406802
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Transition from primary Raynaud's phenomenon to secondary Raynaud's phenomenon identified by diagnosis of an associated disease: results of ten years of prospective surveillance.
    Hirschl M; Hirschl K; Lenz M; Katzenschlager R; Hutter HP; Kundi M
    Arthritis Rheum; 2006 Jun; 54(6):1974-81. PubMed ID: 16732585
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Initial prevalence and incidence of secondary Raynaud's phenomenon in patients with Raynaud's symptomatology.
    Hirschl M; Kundi M
    J Rheumatol; 1996 Feb; 23(2):302-9. PubMed ID: 8882036
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Laser Doppler-recorded venoarteriolar reflex in Raynaud's phenomenon.
    Stoyneva Z
    Auton Neurosci; 2004 Nov; 116(1-2):62-8. PubMed ID: 15556839
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Autoantibodies and microvascular damage are independent predictive factors for the progression of Raynaud's phenomenon to systemic sclerosis: a twenty-year prospective study of 586 patients, with validation of proposed criteria for early systemic sclerosis.
    Koenig M; Joyal F; Fritzler MJ; Roussin A; Abrahamowicz M; Boire G; Goulet JR; Rich E; Grodzicky T; Raymond Y; Senécal JL
    Arthritis Rheum; 2008 Dec; 58(12):3902-12. PubMed ID: 19035499
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Need to expand microvascular investigation of patients with Raynaud's phenomenon of different etiology: clinical patterns of 106 consecutive patients.
    Arpaia G; Cimminiello C; Bellone M; Aloisio M; Rossi F; Bonfardeci G
    Int Angiol; 1994 Mar; 13(1):15-8. PubMed ID: 8077792
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Raynaud's phenomenon: clinical spectrum of 118 patients.
    De Angelis R; Del Medico P; Blasetti P; Cervini C
    Clin Rheumatol; 2003 Oct; 22(4-5):279-84. PubMed ID: 14576990
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of endothelin-1 and selected cytokines in the pathogenesis of Raynaud's phenomenon associated with systemic connective tissue diseases.
    Rychlik-Golema W; Mastej K; Adamiec R
    Int Angiol; 2006 Jun; 25(2):221-7. PubMed ID: 16763543
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pulmonary diffusing capacity disturbances are related to nailfold capillary changes in patients with Raynaud's phenomenon with and without an underlying connective tissue disease.
    Groen H; Wichers G; ter Borg EJ; van der Mark TW; Wouda AA; Kallenberg CG
    Am J Med; 1990 Jul; 89(1):34-41. PubMed ID: 2368791
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Increased circulating platelet-leucocyte complexes in patients with primary Raynaud's phenomenon and Raynaud's phenomenon secondary to systemic sclerosis: a comparative study.
    Pamuk GE; Turgut B; Pamuk ON; Vural O; Demir M; Cakir N
    Blood Coagul Fibrinolysis; 2007 Jun; 18(4):297-302. PubMed ID: 17473568
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diagnostic significance of nailfold capillary patterns in patients with Raynaud's phenomenon. An analysis of patterns discriminating patients with and without connective tissue disease.
    Houtman PM; Kallenberg CG; Fidler V; Wouda AA
    J Rheumatol; 1986 Jun; 13(3):556-63. PubMed ID: 3735277
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The prognostic value of nailfold capillary changes for the development of connective tissue disease in children and adolescents with primary raynaud phenomenon: a follow-up study of 250 patients.
    Pavlov-Dolijanović S; Damjanov N; Ostojić P; Susić G; Stojanović R; Gacić D; Grdinić A
    Pediatr Dermatol; 2006; 23(5):437-42. PubMed ID: 17014637
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The diagnostic value of clinical signs and symptoms in patients with Raynaud's phenomenon. A cross-sectional study.
    Wollersheim H; Thien T
    Neth J Med; 1990 Dec; 37(5-6):171-82. PubMed ID: 2074908
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antinuclear antibodies and connective tissue disease features in fibromyalgia syndrome: a controlled study.
    Yunus MB; Hussey FX; Aldag JC
    J Rheumatol; 1993 Sep; 20(9):1557-60. PubMed ID: 8164214
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Measuring disease activity and functional status in patients with scleroderma and Raynaud's phenomenon.
    Merkel PA; Herlyn K; Martin RW; Anderson JJ; Mayes MD; Bell P; Korn JH; Simms RW; Csuka ME; Medsger TA; Rothfield NF; Ellman MH; Collier DH; Weinstein A; Furst DE; Jiménez SA; White B; Seibold JR; Wigley FM;
    Arthritis Rheum; 2002 Sep; 46(9):2410-20. PubMed ID: 12355489
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oral iloprost treatment in patients with Raynaud's phenomenon secondary to systemic sclerosis: a multicenter, placebo-controlled, double-blind study.
    Wigley FM; Korn JH; Csuka ME; Medsger TA; Rothfield NF; Ellman M; Martin R; Collier DH; Weinstein A; Furst DE; Jimenez SA; Mayes MD; Merkel PA; Gruber B; Kaufman L; Varga J; Bell P; Kern J; Marrott P; White B; Simms RW; Phillips AC; Seibold JR
    Arthritis Rheum; 1998 Apr; 41(4):670-7. PubMed ID: 9550476
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evolution of primary Raynaud's phenomenon (Raynaud's disease) to connective tissue disease.
    Gerbracht DD; Steen VD; Ziegler GL; Medsger TA; Rodnan GP
    Arthritis Rheum; 1985 Jan; 28(1):87-92. PubMed ID: 3871330
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Outcome of positive antinuclear antibodies in individuals without connective tissue disease.
    Myckatyn SO; Russell AS
    J Rheumatol; 2003 Apr; 30(4):736-9. PubMed ID: 12672192
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Platelet activation, fibrinolytic activity and circulating immune complexes in Raynaud's phenomenon.
    Kallenberg CG; Vellenga E; Wouda AA; The TH
    J Rheumatol; 1982; 9(6):878-84. PubMed ID: 7161779
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.